DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05705349 |
Recruitment Status :
Recruiting
First Posted : January 30, 2023
Last Update Posted : May 6, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV-1 Infection | Drug: DOR/ISL Drug: BIC/FTC/TAF Drug: Placebo to DOR/ISL Drug: Placebo to BIC/FTC/TAF | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 500 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in HIV-1 Infected Treatment-Naïve Participants |
Actual Study Start Date : | March 8, 2023 |
Estimated Primary Completion Date : | October 19, 2025 |
Estimated Study Completion Date : | November 1, 2026 |
Arm | Intervention/treatment |
---|---|
Experimental: DOR/ISL
Participants take DOR/ISL and placebo to BIC/FTC/TAF once daily (qd) for 96 weeks.
|
Drug: DOR/ISL
Fixed dose combination tablet containing DOR/ISL 100 mg/0.25 mg taken by mouth.
Other Name: MK-8591A Drug: Placebo to BIC/FTC/TAF Placebo tablet matched to BIC/FTC/TAF tablet taken by mouth. |
Active Comparator: BIC/FTC/TAF
Participants take BIC/FTC/TAF and placebo to DOR/ISL qd for 96 weeks.
|
Drug: BIC/FTC/TAF
Fixed dose combination tablet containing BIC/FTC/TAF 50 mg/200 mg/25 mg taken by mouth. Drug: Placebo to DOR/ISL Placebo tablet matched to DOR/ISL tablet taken by mouth. |
- Percentage of participants with human immunodeficiency virus type 1 (HIV-1) ribonucleic acid (RNA) <50 copies/mL at Week 48 [ Time Frame: Week 48 ]Plasma HIV-1 RNA quantification will be performed at the central laboratory using a polymerase chain reaction (PCR) assay with a lower limit of detection of <50 copies/mL.
- Percentage of participants experiencing ≥1 adverse event (AE) through Week 48 [ Time Frame: Up to 48 weeks ]An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
- Percentage of participants discontinuing from study treatment due to an AE through Week 48 [ Time Frame: Up to 48 weeks ]An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
- Percentage of participants with HIV-1 RNA <50 copies/mL at Week 96 [ Time Frame: Week 96 ]Plasma HIV-1 RNA quantification will be performed at the central laboratory using a PCR assay with a lower limit of detection of <50 copies/mL.
- Percentage of participants with HIV-1 RNA <200 copies/mL at Week 48 [ Time Frame: Week 48 ]Plasma HIV-1 RNA quantification will be performed at the central laboratory using a PCR assay with a lower limit of detection of <50 copies/mL.
- Percentage of participants with HIV-1 RNA <200 copies/mL at Week 96 [ Time Frame: Week 96 ]Plasma HIV-1 RNA quantification will be performed at the central laboratory using a PCR assay with a lower limit of detection of <50 copies/mL.
- Change from baseline in cluster of differentiation 4+ (CD4+) T-cells at Week 48 [ Time Frame: Baseline (Day 1) and Week 48 ]CD4+ T-cells are quantified with a T and B lymphocyte and natural killer cell (TBNK) panel.
- Change from baseline in CD4+ T-cells at Week 96 [ Time Frame: Baseline (Day 1) and Week 96 ]CD4+ T-cells are quantified with a TBNK panel.
- Incidence of viral drug resistance [ Time Frame: Up to 96 weeks ]Plasma samples will be collected for genotypic and phenotypic HIV-1 viral drug resistance testing and used to assess resistance-associated substitutions and viral susceptibility as applicable during the study.
- Change from baseline in body weight at Week 48 [ Time Frame: Baseline (Day 1) and Week 48 ]Body weight will be collected throughout the study.
- Change from baseline in body weight at Week 96 [ Time Frame: Baseline (Day 1) and Week 96 ]Body weight will be collected throughout the study.
- Percentage of participants experiencing ≥1 AE through Week 96 [ Time Frame: Up to 96 weeks ]An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
- Percentage of participants discontinuing from study treatment due to an AE through Week 96 [ Time Frame: Up to 96 weeks ]An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Is HIV-1 positive with plasma HIV-1 RNA ≥500 copies/mL at screening
- Is naïve to antiretroviral therapy (ART) defined as having received no prior therapy with any antiretroviral agent following a diagnosis of HIV-1 infection
- If female, is not a participant of childbearing potential (POCBP); or if a POCBP, is not pregnant or breastfeeding, and is willing to use an acceptable contraceptive method or abstain from heterosexual intercourse for study duration
Exclusion Criteria:
- Has HIV-2 infection
- Has hypersensitivity or other contraindication to any of the components of the study interventions as determined by the investigator
- Has a diagnosis of an active AIDS-defining opportunistic infection within 30 days prior to screening
- Has active hepatitis B infection (defined as hepatitis B surface antigen [HBsAg]-positive or HBV deoxyribonucleic acid [DNA]-positive).
- Has chronic hepatitis C virus (HCV) infection (detectable HCV ribonucleic acid [RNA]) and lab values are consistent with cirrhosis
- Has a history of malignancy ≤5 years prior to providing documented informed consent except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or cutaneous Kaposi's sarcoma
- Has a history or current evidence of any condition (including active tuberculosis infection), therapy, laboratory abnormality, or other circumstance (including drug or alcohol use or dependence) that might, in the opinion of the investigator, confound the results of the study or interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05705349
Contact: Toll Free Number | 1-888-577-8839 | Trialsites@merck.com |
Study Director: | Medical Director | Merck Sharp & Dohme LLC |
Responsible Party: | Merck Sharp & Dohme LLC |
ClinicalTrials.gov Identifier: | NCT05705349 |
Other Study ID Numbers: |
8591A-053 2022-502099-22-00 ( Other Identifier: EU CT ) jRCT2031220720 ( Registry Identifier: jRCT ) |
First Posted: | January 30, 2023 Key Record Dates |
Last Update Posted: | May 6, 2024 |
Last Verified: | May 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf |
URL: | http://engagezone.msd.com/ds_documentation.php |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Islatravir Antiviral Agents Anti-Infective Agents Enzyme Inhibitors |
Molecular Mechanisms of Pharmacological Action Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Anti-Retroviral Agents |